慢性丙型肝炎患者血清白细胞介素-8表达水平及抗病毒治疗后变化

目的探讨慢性丙型肝炎患者血清趋化因子白细胞介素-8(IL-8)的表达水平及抗病毒治疗后的动态变化。方法对74例慢性丙型肝炎患者及30例健康对照的血清标本,应用双抗体夹心ABC-ELISA法进行IL-8检测,并观察了36例聚乙二醇化干扰素联合利巴韦林抗病毒治疗12周后血清IL-8水平的变化。结果慢性丙型肝炎患者血清IL-8水平较健康对照组明显升高,分别为(42.95±50.00)pg/ml及(11.06±1.39)pg/ml(t=3.4831,P=0.0007)。抗病毒12周治疗后,26例HCVRNA低于检测下限者的血清IL-8水平较治疗前明显下降,由(41.29±28.65)pg/ml降至(23.15±10.58)pg/ml(t=3.76,P=0.001);10例HCVRNA仍阳性者血清IL-8水平无明显下降,治疗前后水平分别为(43.79±18.60)pg/ml及(42.38±18.00)pg/ml(t=1.04,P=0.32)。结论慢性丙型肝炎患者血清IL-8表达水平显著升高,提示IL-8参与了慢性丙型肝炎的致病过程,干扰素治疗抑制病毒复制,显著降低了血清IL-8的表达水平。

Expression levels of serum interleukin-8 in patients with chronic hepatitis C and the changes after antivirus treatments

Objective To investigate the expression levels of serum interleukin-8（IL-8）in patients with chronic hepatitis C and the changes after antivirus treatments.Methods The serum levels of IL-8 in 74 patients with chronic hepatitis C and 30 controls were tested by sandwich ABC-ELISA assay.Thirty six patients were treated with PEG-interferon and ribavirin.The titers of IL-8 in patients were compared before and after antivirus treatments for 12 weeks.Results The average level of serum IL-8 in chronic hepatitis C patients were statistically higher than that in healthy controls（42.95±50.00 pg/ml versus 11.06±1.39 pg/ml）,（t=3.4831,P=0.0007）.After treatments,26 patients whose HCV RNA had turned negative in response to antiviral treatments also demonstrated a significant decrease in their average IL-8 titer（from 41.29±28.65 pg/ml to 23.15±10.58 pg/ml）,（t = 3.76,P = 0.001）,while the change of IL-8 levels in other 10 patients whose serum HCV RNA remained positive was not statistically significant（from 43.79±18.60 pg/ml to 42.38±18.00 pg/ml）,（t = 1.04,P = 0.32）.Conclusions Expression levels of serum IL-8 in patients increased compared with healthy controls,which indicated a role of IL-8 in the pathology of chronic hepatitis C.Antiviral therapy could decrease the serum IL-8 levels in responsive patients.The causal relationships between persistently elevated serum IL-8 and failure of antiviral therapy will be discussed.